TetraQ recognized for toxicolog...( TetraQ the integrated preclinical co...),Health
TetraQ, the integrated preclinical contract research provider based at The University of Queensland (UQ), has attained Good Laboratory Practice (GLP) recognition for its toxicology services after satisfying rigorous internationally-benchmarked criteria.
The additional accreditation from the National Association of Testing Authorities (NATA) for another of its key laboratories means that as well as GLP bioanalytical services, TetraQ can provide local and international clients with GLP compliant toxicology services including genotoxicity, dose range-finding, acute and repeat-dose studies.
TetraQ's Executive Director, Professor Maree Smith, said the GLP accreditation for its toxicology and ADME laboratories had now positioned TetraQ as the leading integrated preclinical service provider to the Australian biopharmaceutical industry.
TetraQ's decision to offer toxicology services, including toxicokinetics, allows us to leverage our strong track record in fully-validated bioanalytical method development and sample analysis, Professor Smith said.
We are delighted to be able to offer our clients in Australia and overseas an extended, internationally accredited service delivery which includes acute and chronic toxicology services, said Professor Smith.
These toxicology services include cytotoxicity assays, genotoxicity assays - bacterial mutation (Ames) tests; mouse lymphoma assay; mammalian erythrocyte micronucleus testing; dose range finding; safety pharmacology (cardiovascular, central nervous and respiratory systems); off-target screening; and hERG binding assays.
TetraQ has state-of-the-art facilities and equipment which meet stringent quality and testing standards to conduct toxicology studies that can be recognized by international regulatory authorities.
GLP recognition is required for regulatory submissions on later-stage toxicology studies, and because we have designed our early-stage servic
'/>"/>
| Contact: Rose-Marie Pennisi communications@uq.edu.au 61-733-467-374 Research Australia Source:Eurekalert |
Related medicine news :
1. Blue Cross and Blue Shield Initiatives Recognized for Increasing Patient Safety and Efficiency
2. Health Advocate Recognized by Inc. 500 as One of the Nations Fastest Growing Private Companies
3. J.D. Power and Associates Reports: CIGNA HealthCare Recognized for Call Center Customer Satisfaction Excellence For a Second Consecutive Year
4. J.D. Power and Associates Reports: Hackensack University Medical Center Recognized as First Hospital to Achieve Distinction for Providing an Outstanding Inpatient Experience in All Four Service Areas
5. Common abdominal pain may be due to a potentially treatable newly recognized inflammatory reaction
6. Lauren Marangell, M.D. to Join Lilly; Internationally Recognized Expert in Depression Joins as Distinguished Lilly Scholar
7. J.D. Power and Associates Reports: Rush-Copley Medical Center Recognized for Third Consecutive Year for Providing an Outstanding Inpatient Experience
8. AstraZeneca Recognized as One of Working Mothers 100 Best Companies for the Sixth Consecutive Year
9. Blue Cross and Blue Shield Association Nationally Recognized by BusinessWeek and AARP for Creating a Unique Workplace Environment for New and Mature Employees
10. Higher death rates in kidney patients with newly recognized disease
11. For Second Year Beryl Recognized as a Tech Titan, One of Texas Fastest- Growing Technology Companies
| Copyright © 2003-2009 Bio-Medicine. All rights reserved. ABOUT | CONTACT US | DISCLAIMER | PRIVACY POLICY | TERMS AND CONDITIONS |  |